AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Long-term Debt
Borrowings due after more than one year.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Long-term Debt · Q3 FY2025 · quarter ended Sep 2025
Long-term debt of €0 in Q3 FY2025
Q3 FY2025 long-term debt was €0.
Context
- Long-term debt amounted to 0.0% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
Currency unavailable · from the balance sheet
No Long-term Debt data reported for this period type.
Long-term Debt vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term debt is compared through growth and share of total assets rather than absolute size.
- Long-term debt amounts to 0.0% of total assets for AGMB, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $263.74M USD | — | — | 80.0% | |
| Mar 2026 | $251K USD | — | -52.1% | 0.4% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
ALMSAlumis Inc. Common Stock | Jun 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | — | -52.1% | 0.2% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.